Development and evaluation of innovative devices for detecting falsified and substandard vaccines in supply chains

MRC · United Kingdom government procurement

GlobalGov surfaces government procurement from around the world, including the markets your competitors overlook.

August 30, 2029
Response Due
Active
Status

Opportunity Overview

We are increasingly reliant on safe and effective vaccines to prevent infectious diseases. Over 16 billion vaccines were used in 2021 to tackle the COVID-19 pandemic and >~5 million deaths are prevented annually through immunization with vaccines for >20 other diseases.


WHO estimates that 10.5% of medical products in low- and middle-income countries are substandard or falsified (SF). Some estimate>1 million deaths/year globally. There are increasing reports of SF vaccines in supply chains, risking impaired vaccine effectiveness. Substandard (often degraded by heat) and falsified (due to fraud, aka counterfeit) vaccines are a neglected global public health problem, with minimal research to inform interventions to reduce the risk. There have been multiple examples, involving thousands of patients, both before, during and after the COVID-19 pandemic, e.g. 60,000 injected with fake vaccines in Niger in 1995 and 250,000 substandard vaccines for children distributed in China in 2018. SF vaccines risk not just ineffective disease prevention but economic and societal harms, including impaired trust in vaccines. A major challenge to mitigate SF vaccine risk is a paucity of devices/methods for SF vaccine screening. Multiple devices will be needed to test at different supply chain levels. This represents a major gap in preparing for vaccine-preventable pandemics, epidemics and multiple endemic diseases.


Over the last 5 years we have pioneered research into the development and evaluation of screening devices with high sensitivity and specificity to detect SF vaccines. These include matrix-assisted laser desorption/ionization-time-of-flight mass spectrometry (MALDI-TOF), handheld spatially offset Raman spectroscopy (SORS), and rapid diagnostic tests (RDTs). Importantly, these devices are widely available globally (e.g. SORS for airport security). We work with multiple medicines regulatory authorities, vaccine manufactures, WHO and other national and international...

This is one of 1,831 active United Kingdom Research Development opportunities most of your competitors will never see.

Your competitors are watching the same crowded contracts everyone else is. Track this opportunity and every one like it worldwide, set deadline alerts, and win where they aren’t. Free for 14 days, no card.

Start Free

Solicitation Details

Issuing agencyMRC
CountryUnited Kingdom
CategoryResearch Development
Procurement stageActive solicitation
Response dueAugust 30, 2029
StatusOpen — accepting responses
Official sourceView original notice
Last verifiedAugust 12, 2026

Source: UK Research and Innovation (UKRI) — Open Government Licence v3.0.

Related Opportunities in United Kingdom

Rotation year
Title of project: Evaluation of the quantitative accuracy and radiation dosimetry of an advanced pre-clinical multipinhole SPECT/CT theranostic imag
Discerning MCT1s role in chromatin remodelling and metabolomics changes in cancer progression
Leveraging real world data to characterise the long term impact of COVID-19
Bacterial antibiotic resistance: structure, mechanism and inhibition of ABC transporters responsible for drug efflux and cell wall biogenesis.
Characterising the role of TEX12 in centrosome and cilia development
Allogeneic Chondroprogenitor Therapy (Phase II) (ACT2)
Iron and immunity

See every United Kingdom Research Development opportunity your competition is missing. Free for 14 days.

Get real-time alerts, competitive intelligence, and deadline tracking for this and every market worldwide.

Start Free Trial — No Card Required

Free 14-day trial · no card required

See who is already competing here →

Get a free United Kingdom Research Development intelligence report in your inbox

A personalized report on United Kingdom Research Development opportunities, emailed in 5-10 minutes. One per month, no account needed.